Trial Profile
DRIVESHAFT: Phase IV Randomized, Open-Label Study in HIV-1 Virologically-suppressed Patients On Regimens With Darunavir 600mg/Ritonavir 100mg Twice-daily Switching to Darunavir 800mg/Ritonavir 100mg Once-daily Vs. Continuing Twice-daily Darunavir/Ritonavir Regimens
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Antiretrovirals; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DRIVESHAFT
- 20 Apr 2015 Status changed from active, no longer recruiting to completed a per ClinicalTrials.gov record.
- 23 Mar 2015 According to the the ClinicalTrials.gov record, planned end date changed from 1 Jun 2014 to 1 May 2015.
- 23 Mar 2015 According to the the ClinicalTrials.gov record, planned primary completion date changed to 1 May 2014.